Universitaetsklinikum Heidelberg AöR | ClinicalTrials HQ

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Recruiting	Phase 3	2026-10-07		NCT05243797
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease	Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder	Recruiting	Phase 3	2026-07-28		NCT07280585
Efficacy of INM004 in Children With STEC-HUS	Cytopenia, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Urogenital Diseases, anemia, blood platelet disease, hematologic disorder, hemolytic anemia, hemolytic-uremic syndrome, kidney disorder, thrombocytopenia, thrombotic microangiopathy, uremia, urinary system disorder	Recruiting	Phase 3	2026-01-15		NCT06389474